N-acetylaspartylglutamate in Canavan disease: An adverse effector?

European Journal of Pediatrics

Volumn 158, Issue 5, 1999, Pages 406-409

  Burlina, A P ^f,g   Ferrari, V ^g   Divry, P ^a   Gradowska, W ^b   Jakobs, C ^c   Bennett, M J ^d   Sewell, A C ^g   Dionisi Vici, C ^e   Burlina, A B ^f  

^a HÔPITAL DEBROUSSE   (France)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g NONE

Author keywords

Canavan disease; Capillary zone electrophoresis; N acetylaspartate; N acetylaspartylglutamate; Urine

Indexed keywords

N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADOLESCENT; ARTICLE; CANAVAN DISEASE; CAPILLARY ZONE ELECTROPHORESIS; CEREBROSPINAL FLUID LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INFANT; NEUROCHEMISTRY; NEWBORN; PATHOGENESIS; PRIORITY JOURNAL; URINALYSIS;

ADOLESCENT; CANAVAN DISEASE; CHILD; CHILD, PRESCHOOL; DIPEPTIDES; ELECTROPHORESIS, CAPILLARY; HUMANS; INFANT; INFANT, NEWBORN; NEUROPEPTIDES;

EID: 0013361563     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004310051102     Document Type: Article

References (24)

1. 1. Adachi M, Schneck L, Cara J, Volk BW (1973) Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). Hum Pathol 4:331-347
2. 2. Beaudet AL (1995) Aspartoacylase deficiency (Canavan disease). In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGrawHill, New York, pp 4599-4605
3. 3. Bennett MJ, Gibson KM, Sherwood WG, Divry P, Rolland MO, Elpeleg ON, Rinaldo P, Jakobs C (1993) Reliable prenatal diagnosis of Canavan disease (aspartoacylase deficiency): comparison of enzymatic and metabolite analysis. J Inherit Metab Dis 16:831-836
4. 4. Blakely RD, Coyle JT (1988) The neurobiology of N-acetylaspartylglutamate. Int Rev Neurobiol 30:39-100
5. 5. Burlina AP, Skaper SD, Mazza MR, Ferrari V, Leon A, Burlina AB (1994) N-acetylaspartylglutamate selectively inhibits neuronal responses to N-methyl-D-aspartic acid in vitro. J Neurochem 63:1174-1177
6. 6. Burlina AP, Corazza A, Ferrari V, Erhard P, Künnecke B, Seelig J, Burlina AB (1994) Detection of increased urinary N-acetylaspartylglutamate in Canavan disease (Letter). Eur J Pediatr 153:538-539
7. 7. Burlina AP, Ferrari V, Facci L, Skaper SD, Burlina AB (1997) Mast cells contain large quantities of secretagogue-sensitive N-acetylaspartate. J Neurochem 69:1314-1317
8. 8. Cangro CB, Namboodiri MAA, Sklar LA, Corigliano-Murphy A, Neale JH (1987) Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. J Neurochem 49:1579-1588
9. 9. Cassidy M, Neale JH (1993) Localization and transport of N-acetylaspartylglutamate in cells of whole murine brain in primary culture. J Neurochem 60:1631-1638
10. 10. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634
11. 11. Divry P, Vianey-Liaud C, Gay C, Macabeo V, Rapin F, Echenne B (1988) N-acetylaspartic aciduria: report of three new cases in children with a neurological syndrome associating macrocephaly and leukodystrophy. J Inherit Metab Dis 11:307-308
12. 12. Jakobs C, Ten Brink HJ, Langelaar SA, Zee T, Stellaard F, Macek M, Srsnova K, Srsen S, Kleijer WJ (1991) Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J Inherit Metab Dis 14:653-660
13. 13. Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J (1988) Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 29:463-471
14. 14. Miyake M, Morino H, Mizobuchi M, Kakimoto Y (1982) N-acetyl-L-aspartic acid, N-acetyl-α-L-aspartyl-L-glutamic acid and β-citryl-L-glutamic acid in human urine. Clin Chim Acta 120:119-126
15. 15. Passani LA, Vonsattel JPG, Coyle JT (1997) Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res 772:9-22
16. 13C magnetic resonance spectroscopy. Neurochem Res 11:1245-1251
17. 1H magnetic resonance spectroscopy. Clin Chim Acta 206:137-146
18. 18. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, Pestronk A, Stauch BL, Coyle JT (1990) Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28:18-25
19. 19. Stauch Slusher B, Robinson MB, Tsai G, Simmons ML, Richards SS, Coyle JT (1990) Rat brain N-acetylated α-linked acidic dipeptidase activity. J Biol Chem 265:21297-21301
20. +. J Neurochem 62:2349-2355
21. 21. Tieman SB, Butler K, Neale JH (1988) N-acetylaspartylglutamate: a neuropeptide in the human visual system. J Am Med Assoc 259:2020
22. 22. Tsai G, Coyle JT (1995) N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 46:531-540
23. 23. Valivullah HM, Lancaster J, Sweetnam PM, Neale JH (1994) Interactions between N-acetylaspartylglutamate and AMPA, kainate, and NMDA binding sites. J Neurochem 63:1714-1719
24. 24. Wroblewska B, Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE, Neale JH (1997) N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69:174-181